Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.1 EUR | +3.04% | -1.61% | +30.34% |
Mar. 28 | Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Feb. 06 | Transcript : Apontis Pharma AG - Special Call |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+30.34% | 57.22M | - | ||
+33.46% | 701B | C+ | ||
+26.24% | 570B | B | ||
+0.93% | 381B | C+ | ||
+21.03% | 334B | B- | ||
+17.51% | 322B | C+ | ||
+0.74% | 209B | B+ | ||
+2.95% | 212B | B- | ||
-6.05% | 205B | A+ | ||
-3.61% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock
- Equities
- Stock Apontis Pharma AG
- Stock Apontis Pharma AG - Deutsche Boerse AG
- Ratings Apontis Pharma AG